We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

2 hedge funds and large institutions have $0 invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 181 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 185 → 2 (-183)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.24B → $0 (-$2.24B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 181

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-183
Holders Change %
-98.92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
181
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$198M
2
FLSM
Frazier Life Sciences Management
California
-$167M
3
BlackRock
BlackRock
New York
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$113M
5
State Street
State Street
Massachusetts
-$112M
Name Holding Trade Value Shares
Change 		Change in
Stake
UCFA
151
United Capital Financial Advisors
Texas
– -$292K -7,602 Closed
SO
152
STRS Ohio
Ohio
– -$291K -7,600 Closed
HHGC
153
Hunting Hill Global Capital
New York
– -$286K -7,433 Closed
Zurich Cantonal Bank
154
Zurich Cantonal Bank
Switzerland
– -$283K -7,368 Closed
GH
155
GAM Holding
Switzerland
– -$280K -7,300 Closed
TSS
156
Two Sigma Securities
New York
– -$248K -6,448 Closed
AB
157
Amalgamated Bank
New York
– -$242K -6,310 Closed
VFA
158
Values First Advisors
Tennessee
– -$215K -5,609 Closed
Royal Bank of Canada
159
Royal Bank of Canada
Ontario, Canada
– -$214K -5,562 Closed
AIP
160
Ameritas Investment Partners
Nebraska
– -$184K -4,790 Closed
FIA
161
FNY Investment Advisers
New York
– -$153K -4,000 Closed
Fidelity Investments
162
Fidelity Investments
Massachusetts
– -$138K -3,590 Closed
TRCT
163
Tower Research Capital (TRC)
New York
– -$132K -3,439 Closed
Carson Wealth (CWM LLC)
164
Carson Wealth (CWM LLC)
Nebraska
– -$123K -3,190 Closed
MLICM
165
Metropolitan Life Insurance Company (MetLife)
New York
– -$122K -3,169 Closed
Russell Investments Group
166
Russell Investments Group
United Kingdom
– -$120K -3,121 Closed
CG
167
Cutler Group
California
– -$103K -2,700 Closed
Nisa Investment Advisors
168
Nisa Investment Advisors
Missouri
– -$64.3K -1,674 Closed
N
169
Natixis
France
– -$51.9K -1,352 Closed
Osaic Holdings
170
Osaic Holdings
Arizona
– -$33.8K -880 Closed
CUAMC
171
China Universal Asset Management Company
China
– -$33.7K -876 Closed
Daiwa Securities Group
172
Daiwa Securities Group
Japan
– -$9K -230 Closed
TAM
173
Tucker Asset Management
Colorado
– -$3.84K -100 Closed
WTA
174
Washington Trust Advisors
Massachusetts
– -$2.77K -72 Closed
S
175
SignatureFD
Georgia
– -$2.61K -68 Closed
4 5 6
7
8

KDNY Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2023, worth a combined $0 — down 100% from $2.24B a quarter earlier.

Sellers outnumbered buyers: 181 funds closed out of KDNY and 0 opened new positions — a net loss of 181 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Samsara BioCapital, exiting entirely with an estimated $198M sold.

  • 2 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2023, down from 185 in Q2 2023.
  • Funds reported $0 of Chinook Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2023 and 181 closed out, a net change of -181 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2023 was Samsara BioCapital, an estimated $198M sold.

Based on aggregated 13F filings for Q3 2023.